Article
Tyrosine kinase inhibitors induce alternative spliced BCR-ABLIns35bp variant via inhibition of RNA polymerase II on genomic BCR-ABL.
Cancer science - 1 Jul 2020
Yuda Junichiro, Odawara Jun, Minami Mariko, Muta Tsuyoshi, Kohno Kentaro, Tanimoto Kazuki, Eto Tetsuya, Shima Takahiro, Kikushige Yoshikane, Kato Koji, Takenaka Katsuto, Iwasaki Hiromi, Minami Yosuke, Ohkawa Yasuyuki, Akashi Koichi, Miyamoto Toshihiro
Abstract excerpt
To elucidate dynamic changes in native BCR-ABL and alternatively spliced tyrosine kinase inhibitor (TKI)-resistant but function-dead BCR-ABLIns35bp variant, following commencement or discontinuation of TKI therapy, each transcript was serially quantified in patients with chronic myeloid leukemia (CML) by deep sequencing. Because both transcripts were amplified together using conventional PCR system for measuring...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.